CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Crinetics Pharmaceuticals
CRNX
$3.14B
| $10K | ﹤0.01% |
547
+44
| +9% | +$805 |
|
227
Fate Therapeutics
FATE
$119M
| $9.96K | ﹤0.01% |
987
+78
| +9% | +$787 |
|
228
Regenxbio
RGNX
$461M
| $9.96K | ﹤0.01% |
439
+34
| +8% | +$771 |
|
229
Enanta Pharmaceuticals
ENTA
$192M
| $9.82K | ﹤0.01% |
211
+17
| +9% | +$791 |
|
230
Grifois
GRFS
$6.59B
| $9.6K | ﹤0.01% |
1,129
+86
| +8% | +$731 |
|
231
Pliant Therapeutics
PLRX
$103M
| $9.57K | ﹤0.01% |
495
+39
| +9% | +$754 |
|
232
Innoviva
INVA
$1.32B
| $9.39K | ﹤0.01% |
709
+56
| +9% | +$742 |
|
233
Geron
GERN
$938M
| $9.37K | ﹤0.01% |
3,873
+335
| +9% | +$811 |
|
|
PRVB
234
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $9.37K | ﹤0.01% |
886
+122
| +16% | +$1.29K |
|
235
Allogene Therapeutics
ALLO
$249M
| $9.22K | ﹤0.01% |
1,465
+118
| +9% | +$742 |
|
236
Arcutis Biotherapeutics
ARQT
$1.84B
| $9.16K | ﹤0.01% |
619
+56
| +10% | +$829 |
|
237
AnaptysBio
ANAB
$577M
| $8.96K | ﹤0.01% |
289
+24
| +9% | +$744 |
|
238
IDEAYA Biosciences
IDYA
$2.23B
| $8.89K | ﹤0.01% |
489
+121
| +33% | +$2.2K |
|
239
Veeva Systems
VEEV
$44.1B
| $8.88K | ﹤0.01% |
55
| – | – |
|
240
Lyell Immunopharma
LYEL
$219M
| $8.79K | ﹤0.01% |
2,533
+212
| +9% | +$736 |
|
241
Novavax
NVAX
$1.23B
| $8.78K | ﹤0.01% |
854
+65
| +8% | +$668 |
|
242
Summit Therapeutics
SMMT
$17.7B
| $8.69K | ﹤0.01% |
2,045
+160
| +8% | +$680 |
|
243
Kura Oncology
KURA
$690M
| $8.6K | ﹤0.01% |
693
+67
| +11% | +$831 |
|
244
10x Genomics
TXG
$1.66B
| $8.31K | ﹤0.01% |
228
| – | – |
|
245
Altimmune
ALT
$331M
| $8.21K | ﹤0.01% |
499
+40
| +9% | +$658 |
|
246
Cogent Biosciences
COGT
$1.68B
| $8.21K | ﹤0.01% |
710
+95
| +15% | +$1.1K |
|
247
ARS Pharmaceuticals
SPRY
$1.1B
| $8.13K | ﹤0.01% |
953
+621
| +187% | +$5.3K |
|
248
Collegium Pharmaceutical
COLL
$1.23B
| $7.91K | ﹤0.01% |
341
+21
| +7% | +$487 |
|
249
ADMA Biologics
ADMA
$4.1B
| $7.76K | ﹤0.01% |
1,999
+161
| +9% | +$625 |
|
250
Alector
ALEC
$262M
| $7.75K | ﹤0.01% |
840
+67
| +9% | +$618 |
|